CliffBio
biologic

Nabi-HB

Hepatitis B Immune Globulin (Human)

Loss of exclusivityOctober 2013projected — 12-year biologic exclusivity estimate
CompanyADMA Biologics →See this company's full patent-cliff portfolio

Drug detail

Brand nameNabi-HB
Active ingredientHepatitis B Immune Globulin (Human)
Strength1560IU/5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2001
Marketing statusRx

More from ADMA Biologics

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Nabi-HB patent cliff — loss of exclusivity October 2013 | CliffBio